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Abstract
Background:  Colorectal cancer is the third most common cancer in the western world.
Chemotherapy is often ineffective to treat the advanced colorectal cancers due to the chemo-
resistance. A major contributor to chemo-resistance is tumour-derived inhibition or avoidance of
apoptosis. Insulin-like growth factor I (IGF-I) has been known to play a prominent role in colorectal
cancer development and progression. The role of IGF-I in cancer cell apoptosis is not completely
understood.
Methods: Using three colorectal cancer cell lines and one muscle cell line, associations between
IGF-I and activities of caspase 3/7, 8 and 9 have been examined; the role of insulin-like growth factor
I receptor (IGF-IR) in the caspase activation has been investigated.
Results: The results show that exogenous IGF-I significantly increases activity of caspases 3/7, 8
and 9 in all cell lines used; blocking IGF-I receptor reduce IGF-I-induced caspase activation. Further
studies demonstrate that IGF-I induced caspase activation does not result in cell death. This is the
first report to show that while IGF-I activates caspases 3/7, 8 and 9 it does not cause colorectal
cancer cell death.
Conclusion: The study suggests that caspase activation is not synonymous with apoptosis and that
activation of caspases may not necessarily induce cell death.
Background
Normal human colon consists of many crypts; each crypt
contains several thousand differentiated cells and a small
number of stem cells. Stem cells reside at the bottom of
the crypts and divide slowly and systemically, whereas dif-
ferentiated cells divide rapidly and travel to the top of the
crypt. Each day a total of approximately 1010 cells are shed
into the colon lumen through apoptosis [1]. Apoptosis is
therefore crucial for the maintenance of normal colon
morphology and function. When programmed cell death
does not occur appropriately in the colon, cells that
should be eliminated might persist, become neoplastic
and subsequently develop into colorectal cancer (CRC).
CRC is the third most common cancer in the western
world. Despite advances in the management of this con-
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dition, including improved surgical techniques, the use of
chemo or radiotherapy and, more recently, the use of
screening, the mortality has not changed for decades. At
least 40% of patients with colorectal cancer develop
metastases; chemotherapy alone or in combination with
radiotherapy is usually used as an adjuvant therapy to sur-
gery for the advanced disease [2]. These approaches, how-
ever, are not highly effective against disseminated
colorectal metastases [3]. The major contributor to the
limited effectiveness of treatment is cancer cell resistance
to current chemotherapeutic agents. The most important
mechanism which contributes to chemo-resistance is the
inhibition or avoidance of drug-induced apoptosis.
Caspases play a central role in most apoptotic cell death,
however there is evidence indicated that caspases also
involve with non-apoptotic function. For example, cas-
pase 3 activity is required for skeletal muscle differentia-
tion [4] and terminal differentiation of HT-29 colon
cancer cells is tightly linked to caspase activation [5]. Cas-
pases also play roles in cell motility, migration and some
cell enucleation [6].
It has been established that IGF-I regulates intestinal epi-
thelial cell proliferation, differentiation [7] and that IGF
signalling plays a prominent role in cancer development
and progression [8-10]. Although many studies have
shown that IGF-I is an anti-apoptotic protein, the role of
IGF-I in cellular apoptosis is not completely understood.
Previous studies have shown that IGF-I fully protected
HT-29-D4 colon carcinoma cells undergoing apoptosis
induced by tumour necrosis factor-α [11]. Disrupting the
interaction between IGF-I and its receptor (IGF-IR) with
an IGF-I receptor antagonist significantly increased colon
cancer cell apoptosis [12]. There were also some observa-
tions, however, showing that IGF-I enhances the apop-
totic response to anti-Fas antibody in colorectal cancer
cells [13], potentiates tumour necrosis factor-α induced
apoptosis in adipose-like cells [14], induces apoptosis in
mouse fibroblast cells in the medium with low concentra-
tion of serum [15], and also in mouse skeletal muscle cells
in the presence of tumour necrosis factor-α (TNF-α) [16].
The precise mechanisms by which IGF-I receptors signal
to apoptotic pathways are still unclear. Given the fact that
the IGF system has become an attractive molecular target
for anticancer therapies, it is necessary and important to
determine the relationship between IGF-I pathways and
apoptotic pathways.
We have examined the effect of IGF-I on the activities of
caspase 8, 9 and 3/7 in three colorectal cancer and one
skeletal muscle cell lines. Although these cell lines have
different origins, tissue types, cell types and molecular fea-
tures (table 1), exogenous IGF-I increased the activities of
caspase 3/7, 8 and 9 in all of these cell lines and it appear
that the IGF-I receptor is involved in caspase activation
and the caspase activation does not result in cell death.
Methods
Reagents
Recombinant human IGF-I was purchased from Pepro-
tech EC Ltd (UK). IGF-IR antibody was purchased from
ab-cam (product code: ab16817, Cambridge, UK). Cas-
pase 3/7, Caspase 8 and Caspase 9 activity assay kits and
CellTiter-Blue cell viability assay kits were purchased from
Promega (Madison, USA). Yo Pro-1 iodide was purchased
from Invitrogen (Paisley, UK). Alamar Blue cell prolifera-
tion assay kit was purchased from Serotec Ltd (Oxford,
UK). General Caspase inhibitor, Z-VAD-FMK was pur-
chased from R & D System (Oxford, UK). General mouse
IgG was purchased from Sigma (product number I 5381,
Dorset, UK). All cell culture media, serums and antibiotics
were purchased from GIBCO (UK).
Cell lines and culture conditions
The human colon cancer cell lines HT-29, HCT-116,
SW620 and mouse skeletal muscle cell line C2C12 were
purchased from European Collection of Cell Cultures
(ECACC). HT-29 and HCT-116 cells were cultured in
McCoy's 5A medium containing 2 mM glutamine, 10%
foetal bovine serum and 1% penicillin and streptomycin.
SW620 cells were cultured in L-15 medium containing 2
mM glutamine, 10% foetal bovine serum and 1% penicil-
lin and streptomycin. C2C12 cells were cultured in DMEM
medium containing 10% foetal bovine serum and 1%
penicillin and streptomycin. All cells were cultured and
Table 1: Origins, tissue types, cell types and molecular features of cell lines used in the experiment
Cell line Species Tissue Cell Type APC P53 TGF-β IIR
HT-29 Human Colon Epithelial mut mut wt
HCT-116 Human Colon Epithelial-like wt wt mut
SW620 Human Colon Epithelial mut mut wt
C2C12 Mouse Muscle Myblast wt wt wtBMC Cancer 2009, 9:158 http://www.biomedcentral.com/1471-2407/9/158
Page 3 of 12
(page number not for citation purposes)
maintained at 37°C with 5% CO2/95% air and used at
passages 3–8 after their receipt from the supplier.
Cell treatments
IGF-I treated cell
All cells were seeded on 96 well plates with appropriate
media (HT-29, HCT-116 cells with McCoy's 5A medium,
SW620 cells with L-15 medium and C2C12  cells with
DMEM medium) containing 10% foetal bovine serum
and 1% penicillin and streptomycin at the density of 2 ×
104 cells/well. After 24 hours of culture, HT-29 cells were
treated with different concentrations (0, 1, 10 and 100 ng/
ml) of IGF-I (Peprotech EC Ltd, UK) for 24 or 48 hours
with serum containing medium (SCM, McCoy's 5A
medium containing 10% foetal bovine serum and 1%
penicillin and streptomycin) and serum free medium
(SFM, McCoy's 5A medium containing 1% penicillin and
streptomycin) respectively. HCT-116, SW620 and C2C12
cells were treated with concentration of 0 and 50 ng/ml of
IGF-I for 48 hours with SCM and SFM respectively. After
completion of treatment, cells were subjected to assays for
apoptosis, cell death and cell viability (see following sec-
tion).
IGF-IR antibody neutralizing IGF-I actions in cancer cells
Cells were seeded onto 96 well plates with appropriate
media (HT-29 cells with McCoy's 5A medium and SW620
cells with L-15 medium) containing 10% foetal bovine
serum and 1% penicillin and streptomycin at the density
of 2 × 104 cells/well. After 24 hours of culture, cells were
incubated with IGF-IR antibody (product code: ab16817,
ab-cam, Cambridge, UK) within SCM or SFM medium
respectively at 37°C with 5% CO2/95% air for 30 min-
utes. IGF-I was then added to the wells. The final concen-
tration of IGF-IR antibody in the medium was 400 ng/ml
and IGF-I concentration was 50 ng/ml. Cells were incu-
bated with IGF-IR antibody and IGF-I for further 48 hours
followed by analysis for apoptotic and cell death assays. A
general mouse IgG was also included in the experiment to
check whether any IGF-IR antibody neutralization of IGF-
I action is a specific effect.
Caspase activity assay
Following treatments cells were subjected to Caspase 3/7,
8, 9 activities measurement with Caspase-Glo assay kit
(Promega, Madison USA). Briefly, the plates containing
cells were removed from the incubator and allowed to
equilibrate to room temperature for 30 minutes. 100 μl of
Caspase-Glo reagent was added to each well, the content
of well was gently mixed with a plate shaker at 300–500
rpm for 30 seconds. The plate was then incubated at room
temperature for 2 hours. The luminescence of each sample
was measured in a plate-reading luminometer (Thermo
Labsystems) with parameters of 1 minute lag time and 0.5
second/well read time. The experiments were performed
in triplicate and repeated on two separately-initiated cul-
tures.
Establishment and validation of cell death assay for 
colorectal cancer cell lines (HT-29, SW620 and HCT116)
In order to investigate whether the caspase activation
induces cell death, a previously reported cell death assay
[13] was employed to establish cell death assessment for
HT-29, SW620 and HCT116 cells. Briefly HT-29, SW620
and HCT116 cells were seeded in 96 well plate for 24
hours and then treated with different concentrations
(37.5, 70, 150 and 300 μM) of 5-Fluorouracil (5-FU)
which have been shown to be able to induce apoptosis in
these cell lines [17-19]. After 48 hours treatment, YO
PRO-iodide (Invitrogen) was added to each well at a final
concentration of 4.0 μM/L and the plates were incubated
at 37°C for further 4 hours. The fluorescence was deter-
mined on a fluorescent plate reader (Fluoroskan Ascent
FL; Labsystems, Helsinki, Finland). For the comparison
purpose the cell death index for treated and untreated
cells was calculated with the formula:
where Ft and Fc represent the units of fluorescence (RLU)
in the treated and the untreated cells respectively. The
untreated cell death index would be 1 (Fc/Fc). A cell death
index >1 in the treated cells would indicate more cell
death in the treated group.
Cell death assay
Cells were seeded onto 96 well plates with appropriate
media (HT-29 and HCT116 cells with McCoy's 5A
medium and SW620 cells with L-15 medium) containing
10% foetal bovine serum and 1% penicillin and strepto-
mycin at the density of 2 × 104 cells/well. After 24 hours
of culture, cells were treated with IGF-I at 100 ng/ml con-
centration for 48 hours and then subjected to the cell
death assay using the above methods.
Cell viability assay
A previously reported cell viability assay [20] was
employed to assess the number of viable cell after IGF-I
treatment. Briefly cells were seeded onto 96 well plates
with appropriate media (HT-29 and HCT116 cells with
McCoy's 5A medium and SW620 cells with L-15 medium)
containing 10% foetal bovine serum and 1% penicillin
and streptomycin at the density of 2 × 104 cells/well. Fol-
lowing 24 hours of culture, cells were treated with IGF-I at
the concentration of 100 ng/ml for 48 hours. After treat-
ment 20 μl of CellTiter-Blue reagent (Promega, Madison
USA) was added to each well and mixed for 2 minute on
orbital shaker. Cells were further incubated at 37°C with
5% CO2/95% air for 4 hours. The fluorescence was meas-
ured with excitation at 530 and emission at 620 nm. The
Cell death index Ft Fc = /BMC Cancer 2009, 9:158 http://www.biomedcentral.com/1471-2407/9/158
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CellTiter-Blue cell viability assay provides a fluorometric
method for estimating the number of viable cells. Living
cells posses the ability to reduce resazurin into resosurfin,
which is highly fluorescent. Nonviable cells, due to loss of
metabolic capacity, do not reduce the CellTiter-Blue rea-
gent and thus do not generate a fluorescent signal.
Inhibition of caspases and cell proliferation assay
In order to investigate whether IGF-I-induced caspase acti-
vation has any effect on cancer cell proliferation, a general
caspase inhibitor, Z-VAD-FMK (R & D System, Oxford,
UK) was used to inhibit caspase activity induced by exog-
enous IGF-I. Briefly cells were seeded onto 96 well plates
with appropriate media (HT-29 and HCT116 cells with
McCoy's 5A medium and SW620 cells with L-15 medium)
containing 10% foetal bovine serum and 1% penicillin
and streptomycin at the density of 2 × 104 cells/well. Fol-
lowing 24 hours of culture, cells were treated with either
IGF-I (100 ng/ml) only or IGF-I (100 ng/ml) plus Z-VAD-
FMK (100 μM) for 48 hours. After treatment, 20 μl of
Alamar blue (Serotec Ltd, Oxford, UK) was added to each
well and mixed for 2 minute on orbital shaker. Cells were
further incubated at 37°C with 5% CO2/95% air for 4
hours. The fluorescence was measured with excitation at
530 and emission at 620 nm. Alamar blue assay is a redox
method to measure the proliferation of various human
and animal cell lines and has been proposed as an alter-
native method to MTT assay [21].
Statistical Analysis
All data have been examined and followed a normal dis-
tribution. All results were expressed as mean ± SEM. One
way ANOVA (Prism version 4 2004 edition, USA) with
multiple comparison test was used. Statistical analysis was
perform on n = 6 samples and Bonferroni's Multiple
Comparison Test was used after ANOVA. P < 0.05 is con-
sidered as significant and indicated as *; P < 0.01 is con-
sidered as higher significance and indicated as **. P > 0.05
is considered as not significant and marked as NS.
Results
IGF-I increased caspases 3/7, 8 and 9 activities in colorectal 
cancer cells
To assess the effect of IGF-I on the activities of the main
caspases (caspase 3/7, 8 and 9) in colorectal cancer cells,
we treated the human HT-29 cell line with different con-
centrations of recombinant human IGF-I for 24 and 48
hours. The caspase activity was evaluated with cell-based
homogeneous caspase-glo assay kit in serum containing
medium (SCM, figure 1a–f) and serum free medium
(SFM, figure 1g–l). The results shown that after treatment
with IGF-I for 24 and 48 hours, HT-29 cellular caspase 3/
7 activities increased in both SCM and SFM conditions in
a dose dependent manner (figures 1a, b, g and 1h). It has
been recognized that caspase 3/7 is activated by caspases
8 or 9, therefore these two caspases activity was also meas-
ured using the same methods under the same conditions
(SCM and SFM). The results demonstrate that after treat-
ment with IGF-I, the activity of the caspase 8 (figures 1c,
d, i and 1j) and 9 (figure 1e, f, k and 1l) also increased in
SCM and SFM conditions in a dose dependant manner.
Caspase 8 activation is the step immediately following
death-inducing signalling complex (DISC) formation.
The latter is the part of the extrinsic apoptosis pathway
which involves death ligands bound to cell surface death
receptors. Caspase 9 activation is a part of the intrinsic
apoptosis pathway, which involves cytochrome C release
from the mitochondria [22]. It is interesting to note that
although IGF-I increased in all three caspases (3/7, 8 and
9) activities in both SCM and SFM conditions, the level of
these caspases activity in SFM conditions (figure 1g–l) is
considerably higher than those in SCM conditions (figure
1a–f). This finding is consistent with a previous report
which demonstrated that serum deprivation induced
apoptosis [14]. Collectively these data suggested that IGF-
I treatment increases human colon cancer HT-29 cell cas-
pase 3/7, 8 and 9 activity under both SCM and SFM con-
ditions.
To gain further insight into the IGF-I induced caspase acti-
vation with other cells; we extended the experiments to
SW620 and HCT-116 colorectal tumour cells and C2C12
myoblast cells. The results demonstrate that addition of
IGF-I also significantly increased activity of caspase 3/7
(figure 2a), 8 (figure 2b) and 9 (figure 2c) in HCT-116
CRC cells in both SCM and SFM conditions. For SW620
and C2C12 cells inclusion of IGF-I in both serum contain-
ing and serum free medium also significantly increased
caspase 3/7 activities (figure 2d and 2e). Although the cel-
lular properties (including species, tissue type, cell type
and gene mutations) in four cell lines used are heteroge-
neous (table 1), IGF-I universally increased caspase activ-
ities in all four cell lines.
IGF-I activate caspases 3/7, 8 and 9 in colon cancer cells via 
IGF type 1 receptor
To elucidate whether IGF-I activation of caspases 3/7, 8
and 9 is due to the interaction between IGF-I and its recep-
tors, a neutralised anti-IGF type 1 receptor antibody (IGF-
IR ab) was used to interfere with the binding of IGF-I to its
receptors in cells. The results show that after 48 hours of
IGF-I treatment the activity of caspases 3/7, 8 and 9 in HT-
29 cells significantly increased in both SCM (figure 3a, c
and 3e) and SFM (figure 3b, d and 3f) mediums. When
IGF-IR ab was included in the IGF-I treated cells, the cas-
pase 3/7 activities significantly decreased (P < 0.05) in
both SCM (figure 3a) and SFM (figure 3b) mediums com-
pared to IGF-I treated groups, while the caspase 8 and 9
activities significantly decreased (P < 0.01) in both SCM
(figure 3c and 3e) and SFM (figure 3d and 3f). All theseBMC Cancer 2009, 9:158 http://www.biomedcentral.com/1471-2407/9/158
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IGF-I activate caspases 3/7, 8 and 9 in HT-29 cells Figure 1
IGF-I activate caspases 3/7, 8 and 9 in HT-29 cells.  IGF-I activate caspases 3/7 (a, b, g, h), 8 (c, d, i, j) and 9 (e, f, k, l) in 
HT-29 cells in serum containing (SCM, a-f) and serum free (SFM, g-l) media following the treatment with different concentra-
tions of IGF-I (1, 10, and 100 ng/ml) for 24 and 48 hours. Significance value: * P <0.05; ** P <0.01 compared to untreated cells.   
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IGF-I activate caspases 3/7, 8 and 9 in HCT116, SW620 and C2C12 cells Figure 2
IGF-I activate caspases 3/7, 8 and 9 in HCT116, SW620 and C2C12 cells  IGF-I activate caspase 3/7 (a), 8(b) and 9 (c) 
in serum containing media (SCM) and serum free medium (SFM) in HCT 116 cells following the treatment with IGF-I (50 ng/ml) 
for 48 hours. IGF-I activate caspase 3/7 in SW620 cells (d) and C2C12 cells (e) in serum containing media (SCM) and serum free 
media (SFM) for 48 hours.  Significance value: * P <0.05; ** P <0.01 compared to untreated cells.   
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IGF-I -induced caspases activation is neutralised by anti-IGF-IR antibody Figure 3
IGF-I -induced caspases activation is neutralised by anti-IGF-IR antibody  IGF-I-induced activation of caspases 3/7 (a, 
b), 8 (c, d) and 9 (e, f) in HT-29 cells and caspase 3/7 in SW620 cells (g, h) is neutralised by anti-IGF type 1 receptor antibody 
(IGF-IR ab). Cells were pre-incubated with (+) or without (-) IGF-IR ab (400 ng/ml) for 30 minutes and then treated with (+) or 
without (-) IGF-I (50 ng/ml) for 48 hours. The cellular caspase 3/7, 8 and 9 activities were analysed with Caspase-Glo assay kit 
(Promega, Madison USA). To check whether any IGF-IR antibody neutralization of IGF-I action is a specific effect a general 
mouse IgG was included (i, j). For mouse IgG control experiment cells were pre-incubated with (+) or without (-) mouse IgG 
(400 ng/ml) for 30 minutes. The caspase 3/7 activity was analysed with the same method as IGF-IR ab. Significance value: * P 
<0.05; ** P <0.01. SCM-serum containing media; SFM-serum free media. 
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data show that the caspase 3/7, 8 and 9 activation by IGF-
I can be inhibited by interfering in the binding between
IGF-I and its receptors and indicate that IGF-I activates
caspases 3/7, 8 and 9 in HT-29 cells via interaction
between IGF-I and its receptors. In SCM medium (figure
3a, c and 3e) IGF-IR ab did not affect caspase 3/7, 8 or 9
activity if the medium did not include exogenous IGF-I
compared to untreated groups. However, in SFM medium
the caspase 8 (figure 3d) and 9 (figure 3f) activities tend
to be lower in IGF-IR ab treated group compared to
untreated groups, although these differences did not reach
a statistically significant level. The same effect of blocking
the IGF-I receptor with IGF-I R ab was also shown in
SW620 cells (figure 3g and 3h). When IGF-IR ab was
included in SW620 cells, the caspase 3/7 activities signifi-
cantly decreased (P < 0.01) in both SCM (figure 3g) and
SFM (figure 3h) media compared to IGF-I treated groups.
In order to check whether IGF-IR antibody neutralization
of IGF-I action is a specific effect; a general mouse IgG was
included in the experiment. The results (figure 3i and 3j)
showed that general mouse IgG was not able to inhibit
IGF-I induced caspase activation. This indicates that IGF-
IR antibody effect is a specific action.
Establishment of cell death assay for colorectal cancer cell 
lines (HT-29, SW620 and HCT116)
After treatment with different concentration of 5-FU,
death indexes of HT-29, SW620 and HCT116 cells are
shown in figure 4a, b and 4c respectively. Although all
three cell lines' death index increased in a dose responsive
manner along with the increases of 5-FU concentrations,
it is interesting to note that the three colorectal cell lines
have different sensitivities to the treatments of 5-FU.
While HCT116 cells have the most sensitive responses to
5-FU treatment (figure 4c), HT-29 and SW620 cells only
show modest response (figure a and b). These different
responses may be due to the divergent genetic background
of these cells. HCT116 cell is a p53 wild type of colorectal
cancer cell line while HT-29 and SW620 cells contain
mutated p53 genes (table 1). Both pre-clinical and clinical
studies have shown that disruption of p53 function con-
tributes to 5-FU resistance[23,24]. Never the less, the
results have indicated that the death assay can truly repre-
sent the actual cell death in each treatment. This death
assay method has been successfully used to determine the
apoptotic cell death for HT-29 D4, HCT116 and SW620
cells [13]. It is therefore suitable for assessment of cell
death in HT-29, SW620 HCT116 cells.
IGF-I activation of caspases 3/7, 8 and 9 in colon cancer 
cells does not induce cell death
To further examine whether IGF-I activation of caspases 3/
7, 8 and 9 increases apoptosis in colon cancer cells, HT-
29, SW620 and HCT116 cells were treated with IGF-I (100
ng/ml) in SCM and SFM conditions respectively for 48
hours. The cell death index was then determined using
our established method. The results are shown in figure
4d, e and 4f. It can be seen that cell death is not influenced
by exogenous IGF-I at a 100 ng/ml concentration for all
three cell lines in SCM and SFM conditions, even though
this concentration of IGF-I significantly increase caspase
3/7, 8 and 9 activities in these cell lines (figure 1 and 2).
To further confirm that cell death is not induced by cas-
pase activation a previously reported cell viability assess-
ment [12] was used to examine cell survival after
treatment with exogenous IGF-I. The results are shown in
figure 4g, h and 4i. It can again be seen that cell survival is
not significantly different between IGF-I treated and
untreated cells in SCM and SFM conditions. These results
indicate that IGF-I induced caspase activation alone is not
able to be transformed to the ultimate death signal in
these colon cancer cells.
Inhibition of caspase activation induced by IGF-I does not 
affect cell proliferation
To investigate whether IGF-I-induced caspase activation
has any effect on cancer cell proliferation, caspase activa-
tion induced by IGF-I was inhibited by incubation with Z-
VAD-FMK (a general caspase inhibitor). It was shown that
Z-VAD-FMK indeed was able to inhibit caspase 3 activa-
tion in HT-29 (figure 5a), SW620 (figure 5c) and HCT116
cells (figure 5e). But this inhibition has no effect on these
cell lines' proliferation (figure b, d and f). These indicate
that IGF-I-induced caspase activation has no effect on
these cancer cells' proliferation.
Discussion
IGF-I signalling through the IGF-IR plays an important
role in cellular transformation, proliferation and apopto-
sis of tumour cells. It has been well documented that IGF-
IR has the function of mitogenicity, transformation and
anti-apoptosis in many cell types, both in vitro and in vivo
[25-27]. In addition to the anti-apoptotic action of IGF-I,
there have been several studies which demonstrated that
IGF-I can also be pro-apoptotic in colon cancer cells [13],
skeletal myoblasts [16], preadipocytes [14], fibroblasts
[15] and osteosarcoma cells [28]. The mechanisms by
which IGF-I enhances apoptosis in these cells are still
largely unclear. This study examined the relation of exog-
enous IGF-I and the activities of caspase 3/7, 8 and 9 in
three colorectal cancer cell lines and one skeletal muscle
cell line. It was found that exogenous IGF-I can activate
caspases 3/7, 8 and 9 in all four cell lines, and that the acti-
vation is via the IGF-I receptor. The four cell lines used in
the experiments have a variety of cellular properties
including cell species, tissue type, cell type and gene muta-
tions (table 1), nevertheless, IGF-I universally increased
caspase activities in all of these cell lines, indicating that
caspase activation by exogenous IGF-I is a global effect in
all these cells.BMC Cancer 2009, 9:158 http://www.biomedcentral.com/1471-2407/9/158
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Exogenous IGF-I dose nod change cell death and viability in HT-29, SW620 and HCT116 cells Figure 4
Exogenous IGF-I dose nod change cell death and viability in HT-29, SW620 and HCT116 cells. HT-29 (a), SW620 
(b) and HCT116 (c) cells were treated with different concentrations of 5-Fluorouracil (5-FU) (0, 37.5, 75, 150 and 300 μM) for 
48 hours. The cell death index was determined by a previously reported method  [13]. HT-29 (d), SW620 (e) and HCT116 (f) 
cells were treated with IGF-I (100 ng/ml) for 48 hours and cell death index was determined with the same method. HT-29 (g), 
SW620 (h) and HCT116 (i) cells were treated with IGF-I (100 ng/ml) for 48 hours and cell viability was determined by a previ-
ously reported cell proliferation assay [20].
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Inhibition of IGF-I-induced caspases activation does not affect colorectal cancer cell proliferation Figure 5
Inhibition of IGF-I-induced caspases activation does not affect colorectal cancer cell proliferation. The IGF-I-
induced caspase activation is inhibited by incubation with Z-VAD-FMK (a general caspase inhibitor) for 48 hours. The caspase 
3/7 activity was measured with Caspase-Glo assay kit (Promega, Madison USA). Cell proliferation was measured with Alamar 
blue (Serotec Ltd, Oxford, UK). It was shown that Z-VAD-FMK indeed was able to inhibit caspase 3 activation in HT-29 (a), 
SW620 (c) and HCT116 cells (e). But the inhibition has no effect on cell proliferation (b, d and f).
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Mutational analyses of the IGF-IR have shown that
mitogenicity and transforming activity of IGF-IR are local-
ized on separate domains [29-31]. Point mutation in the
C terminal of IGF-IR abolished its anti-apoptosis and
transformation action, but left its mitogenic action intact
[29,32]. Although the molecular mechanism related to
pro-apoptotic action of IGF-I R remain unclear, expres-
sion of the IGF-IR C terminal as a myristylated protein
caused massive cell death [33] indicating IGF-IR C termi-
nal plays a critical role in regulating cell apoptosis. It has
also been proposed that segregation of IGF-IR in and out
of membrane lipid rafts may regulate the pro and anti-
apoptotic effects of IGF-I [13]. The finding that IGF-I acti-
vation of caspases in colorectal cancer and C2C12 cells
can be inhibited by blocking IGF-I binding to IGF-IR
receptor in this study shows that IGF-IR indeed is involved
in regulation of IGF-I-induced caspase activation. It is
interesting to note that in some conditions IGF-I R ab only
partially inhibit IGF-I induced caspase activation and
inhibition effect is more effective in SFM conditions than
in SCM conditions (figure 3). This indicates that there
may be another receptor or growth factor which is
involved in the caspase activation.
Although it is widely assumed that the apoptotic death of
mammalian cells is closely associated with activation of
caspases, there is evidence indicating that caspase activa-
tion is also involved with processes that are not necessar-
ily related to apoptosis. For examples, caspase 3 activity is
involved with skeletal muscle differentiation [4] and
when HT-29 cells are induced to the terminal differentia-
tion caspase activation is required [5]. It has been reported
that caspase activation may contribute to subtle signalling
pathways, some of which may enhance cell survival and
proliferation [34]. Our results showed that IGF-I activates
caspases 3/7, 8 and 9 in colorectal cancer calls, but did not
cause cell death. This indicates that caspase activation
induced by exogenous IGF-I may be involved with proc-
esses not related to the apoptotic cell death. A further
study is currently investigating the role of IGF-I induced
caspase activation. These findings raise an important
question, i.e. caspase activation is not synonymous with
apoptotic death; therefore increased caspase activities can
not be regarded as a sole indicator of cell death.
Conclusion
IGF-I activates caspase 3/7, 8 and 9 in three colon cancer
and one skeletal muscle cell lines and IGF-IR is involved
in the IGF-I induced caspase activation. IGF-I induced cas-
pase activation is not able to be transformed to death sig-
nal; it may be involved with other processes which are not
related to apoptosis.
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